Cargando…

Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing–remitting MS

BACKGROUND: Neurodegeneration in multiple sclerosis (MS) may be investigated in the visual system as optical coherence tomography (OCT) and magnetic resonance imaging (MRI) allows examining structural integrity in detail. The association between thickness of retinal layers and focal cortical volumes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stellmann, Jan‐Patrick, Cetin, Hanife, Young, Kim Lea, Hodecker, Sibylle, Pöttgen, Jana, Bittersohl, Diana, Hassenstein, Andrea, Oberwahrenbrock, Timm, Heesen, Christoph, Siemonsen, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318367/ https://www.ncbi.nlm.nih.gov/pubmed/28239524 http://dx.doi.org/10.1002/brb3.614

Ejemplares similares

Reduced rich-club connectivity is related to disability in primary progressive MS
por: Stellmann, Jan-Patrick, et al.
Publicado: (2017)

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting
por: von Gumberz, Johanna, et al.
Publicado: (2016)

Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability
por: Has Silemek, Arzu Ceylan, et al.
Publicado: (2020)

Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?
por: Stellmann, Jan-Patrick, et al.
Publicado: (2015)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Ruxolitinib treatment in a patient with neuromyelitis optica: A case report
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosis—a randomized controlled trial
por: Baquet, Lisa, et al.
Publicado: (2018)

Magnetic Resonance Imaging in Multiple Sclerosis – Patients' Experiences, Information Interests and Responses to an Education Programme
por: Brand, Judith, et al.
Publicado: (2014)

Regional gray matter atrophy and neuropsychologcal problems in relapsing-remitting multiple sclerosis
por: Lin, Aiyu, et al.
Publicado: (2013)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients
por: Thaler, Christian, et al.
Publicado: (2015)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Pilot study of a ketogenic diet in relapsing-remitting MS
por: Brenton, J. Nicholas, et al.
Publicado: (2019)

Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients
por: Bester, Maxim, et al.
Publicado: (2015)

T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis
por: Thaler, Christian, et al.
Publicado: (2017)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Cost Effectiveness Analysis of Avonex and CinnoVex in Relapsing Remitting MS
por: Najafi, Behzad, et al.
Publicado: (2015)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
por: Camu, William, et al.
Publicado: (2019)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
por: Nash, Richard A., et al.
Publicado: (2017)

Correction: Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients
por: Bester, Maxim, et al.
Publicado: (2015)

Smartphone Accelerometry: A Smart and Reliable Measurement of Real-Life Physical Activity in Multiple Sclerosis and Healthy Individuals
por: Zhai, Yuyang, et al.
Publicado: (2020)

Risk knowledge of people with relapsing-remitting multiple sclerosis – Results of an international survey
por: Giordano, Andrea, et al.
Publicado: (2018)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
por: Sips, Fianne L. P., et al.
Publicado: (2022)

Regional Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: Baseline Analysis of Multi-Center Data
por: Datta, Sushmita, et al.
Publicado: (2015)

Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis
por: Jonkman, Laura E., et al.
Publicado: (2015)

Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021)

Introducing a new method to assess vision: Computer-adaptive contrast-sensitivity testing predicts visual functioning better than charts in multiple sclerosis patients
por: Stellmann, JP, et al.
Publicado: (2015)

Cognitive performance shows domain specific associations with regional cortical thickness in multiple sclerosis
por: Stellmann, Jan-Patrick, et al.
Publicado: (2021)

Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study()
por: Narayana, Ponnada A., et al.
Publicado: (2012)

The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction?
por: Marrie, Ruth Ann
Publicado: (2017)

Heterogeneity of Multiple Sclerosis Lesions in Multislice Myelin Water Imaging
por: Faizy, Tobias Djamsched, et al.
Publicado: (2016)

Gray Matter Alterations in Early and Late Relapsing-Remitting Multiple Sclerosis Evaluated with Synthetic Quantitative Magnetic Resonance Imaging
por: Andica, Christina, et al.
Publicado: (2019)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
por: Tao, Yazhong, et al.
Publicado: (2015)

Longitudinal changes in the expression of IL-33 and IL-33 regulated genes in relapsing remitting MS
por: Sriram, Subramaniam, et al.
Publicado: (2018)

Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis
por: Stürner, Klarissa Hanja, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_08tmk6jhred9ag6s54oedgjeb2